Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.101379
Revised: November 4, 2024
Accepted: November 22, 2024
Published online: February 15, 2025
Processing time: 127 Days and 22.8 Hours
In this article, we comment on the article published by Yu et al. By employing LASSO regression and Cox proportional hazard models, the article identified nine significant variables affecting survival, including body mass index, Karnofsky performance status, and tumor-node-metastasis staging. We firmly concur with Yu et al regarding the vital significance of clinical prediction models (CPMs), including logistic regression and Cox regression for assessment in esophageal carcinoma (EC). However, the nomogram's limitations and the complexities of integrating genetic factors pose challenges. The integration of immunological data with advanced statistics offers new research directions. High-throughput sequencing and big data, facilitated by machine learning, have revolutionized cancer research but require substantial computational resources. The future of CPMs in EC depends on leveraging these technologies to improve predictive accuracy and clinical application, addressing the need for larger datasets, patient-reported outcomes, and regular updates for clinical relevance.
Core Tip: Clinical prediction model has great development space and practical value in the medical field. Despite significant efforts to explore the prognosis of esophageal carcinoma, current prognostic models remain imperfect. Traditional predictive models, such as Cox proportional hazards regression and logistic regression, are widely used but often lack effective evaluation mechanisms to determine their optimal performance. Moreover, due to limitations in sample size and predictive factors, the reproducibility of these models is poor, which severely restricts their broad application in clinical practice. Therefore, it is necessary to further explore and select more appropriate analytical methods to construct more accurate and reliable predictive models, thereby better serving clinical needs.